Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$2.12 +0.5%	$2.45	$1.28 ▼ $7.85	$232.97M	1.3	1.55 million shs	843,480 shs
CTNM Contineum Therapeutics	$10.05 +0.4%	$5.75	$3.35 ▼ $20.30	$281.82M	1.04	145,038 shs	212,446 shs
GNTA Genenta Science	$3.83 +1.3%	$3.61	$2.74 ▼ $7.28	$70.07M	0.62	14,910 shs	6,564 shs
HUMA Humacyte	$1.58 +3.3%	$2.18	$1.15 ▼ $6.77	$250.23M	1.9	4.03 million shs	3.68 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	-1.86%	-1.40%	-15.26%	-3.21%	-65.12%
CTNM Contineum Therapeutics	+2.14%	+12.85%	+81.67%	+180.39%	-49.62%
GNTA Genenta Science	+7.39%	+11.21%	+0.77%	-11.50%	-7.80%
HUMA Humacyte	+4.08%	-6.13%	-38.06%	-44.77%	-77.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANNX Annexon	2.6217 of 5 stars	3.4	3.0	2.9	2.5	0.0
CTNM Contineum Therapeutics	3.1744 of 5 stars	3.6	5.0	2.7	0.8	0.6
GNTA Genenta Science	2.3549 of 5 stars	3.5	3.0	2.5	1.7	0.0
HUMA Humacyte	2.1524 of 5 stars	3.5	2.0	1.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	2.75	Moderate Buy	$12.50	489.62% Upside
CTNM Contineum Therapeutics	3.17	Buy	$22.75	126.37% Upside
GNTA Genenta Science	3.00	Buy	$25.00	552.57% Upside
HUMA Humacyte	3.00	Buy	$9.75	517.09% Upside

Current Analyst Ratings Breakdown

Latest GNTA, CTNM, HUMA, and ANNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	HUMA Humacyte	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$3.50
8/18/2025	ANNX Annexon	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/18/2025	CTNM Contineum Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$20.00 ➝ $21.00
8/15/2025	ANNX Annexon	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/12/2025	HUMA Humacyte	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.50
8/12/2025	HUMA Humacyte	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
8/11/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/23/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/20/2025	CTNM Contineum Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$1.81 per share	N/A
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	$6.11 per share	N/A
GNTA Genenta Science	N/A	N/A	N/A	N/A	$0.74 per share	N/A
HUMA Humacyte	$1.57M	159.38	N/A	N/A	$0.03 per share	52.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$138.20M	-$1.29	N/A	N/A	N/A	N/A	-70.04%	-57.67%	11/13/2025 (Estimated)
CTNM Contineum Therapeutics	-$42.26M	-$2.20	N/A	N/A	N/A	N/A	-29.75%	-28.08%	11/5/2025 (Estimated)
GNTA Genenta Science	-$9.64M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	-$148.70M	-$0.45	N/A	N/A	N/A	N/A	N/A	-78.26%	11/14/2025 (Estimated)

Latest GNTA, CTNM, HUMA, and ANNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ANNX Annexon	-$0.36	-$0.34	+$0.02	-$0.34	N/A	N/A
8/11/2025	Q2 2025	HUMA Humacyte	-$0.15	-$0.24	-$0.09	-$0.24	$0.94 million	$0.30 million
8/5/2025	Q2 2025	CTNM Contineum Therapeutics	-$0.56	-$0.62	-$0.06	-$0.62	$7.50 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
GNTA Genenta Science	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	5.67	5.67
CTNM Contineum Therapeutics	N/A	24.51	24.51
GNTA Genenta Science	N/A	6.89	6.89
HUMA Humacyte	2.97	2.45	1.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
CTNM Contineum Therapeutics	N/A
GNTA Genenta Science	15.13%
HUMA Humacyte	44.71%

Insider Ownership

Company	Insider Ownership
ANNX Annexon	11.87%
CTNM Contineum Therapeutics	11.30%
GNTA Genenta Science	28.99%
HUMA Humacyte	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	60	109.89 million	96.84 million	Optionable
CTNM Contineum Therapeutics	31	28.04 million	24.87 million	N/A
GNTA Genenta Science	7	18.29 million	12.99 million	Not Optionable
HUMA Humacyte	150	158.37 million	150.30 million	Optionable

GNTA, CTNM, HUMA, and ANNX Headlines

Recent News About These Companies

Humacyte, Inc. (NASDAQ:HUMA) Receives Consensus Rating of "Buy" from Analysts

August 28 at 3:10 AM | marketbeat.com

Humacyte initiated with an Overweight at Barclays

August 27 at 9:33 AM | msn.com

Humacyte, Inc. (NASDAQ:HUMA) Receives Consensus Recommendation of "Buy" from Analysts

August 26 at 3:11 AM | americanbankingnews.com

Monashee Investment Management LLC Buys New Shares in Humacyte, Inc. $HUMA

August 23, 2025 | marketbeat.com

Humacyte (NASDAQ:HUMA) CEO Laura Niklason Sells 591,685 Shares

August 21, 2025 | insidertrades.com

1,049,828 Shares in Humacyte, Inc. $HUMA Acquired by Maven Securities LTD

August 21, 2025 | marketbeat.com

Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views?

August 20, 2025 | zacks.com

Wall Street Zen Downgrades Humacyte (NASDAQ:HUMA) to Sell

August 19, 2025 | americanbankingnews.com

Humacyte (NASDAQ:HUMA) Downgraded by Wall Street Zen to "Sell"

August 18, 2025 | marketbeat.com

What is HC Wainwright's Forecast for Humacyte Q3 Earnings?

August 16, 2025 | marketbeat.com

FY2029 EPS Estimates for Humacyte Cut by HC Wainwright

August 15, 2025 | marketbeat.com

TD Cowen Cuts Humacyte (NASDAQ:HUMA) Price Target to $3.50

August 13, 2025 | marketbeat.com

Humacyte (NASDAQ:HUMA) Price Target Cut to $3.00 by Analysts at HC Wainwright

August 13, 2025 | marketbeat.com

Humacyte’s Earnings Call: Progress Amid Challenges

August 13, 2025 | msn.com

Humacyte Inc. (HUMA) Stock Price Today - WSJ

August 12, 2025 | wsj.com

Durham biotech sees stock plunge on slow sales

August 12, 2025 | bizjournals.com

Humacyte, Inc. (NASDAQ:HUMA) Q2 2025 Earnings Call Transcript

August 12, 2025 | msn.com

Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress

August 12, 2025 | seekingalpha.com

D. Boral Capital Reaffirms "Buy" Rating for Humacyte (NASDAQ:HUMA)

August 12, 2025 | marketbeat.com

Humacyte (NASDAQ:HUMA) Posts Earnings Results, Misses Estimates By $0.09 EPS

August 12, 2025 | marketbeat.com

Humacyte targets over 200 hospital access points for Symvess as VAC approvals surge and cost cuts extend cash runway

August 12, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNTA, CTNM, HUMA, and ANNX Company Descriptions

Annexon NASDAQ:ANNX

$2.12 +0.01 (+0.47%)

Closing price 04:00 PM Eastern

Extended Trading

$2.12 0.00 (-0.24%)

As of 04:56 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Contineum Therapeutics NASDAQ:CTNM

$10.05 +0.04 (+0.40%)

Closing price 04:00 PM Eastern

Extended Trading

$10.31 +0.26 (+2.63%)

As of 04:37 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Genenta Science NASDAQ:GNTA

$3.83 +0.05 (+1.32%)

As of 04:00 PM Eastern

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

Humacyte NASDAQ:HUMA

$1.58 +0.05 (+3.27%)

Closing price 04:00 PM Eastern

Extended Trading

$1.60 +0.02 (+1.58%)

As of 05:45 PM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time